Delcath Systems, Inc. DCTH
14.40 USD +0.11 (+0.77%)
At closeNov 3, 2026, 4:01 PM EST
14.40 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
14.20 Day range 14.52
8.12 52-week range 17.42
- YTD
- +42.57%
- 1 year
- +51.26%
News
businesswire.com Delcath Systems to Participate in Upcoming Investor Conferences QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
businesswire.com Delcath Systems to Host Third Quarter 2026 Earnings Call QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it…
benzinga.com Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical…
businesswire.com Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
benzinga.com Delcath Systems Q2 2026 Earnings Call Transcript Delcath Systems (NASDAQ:DCTH) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
defenseworld.net Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $23.17 Shares of Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm,…
zacks.com Are Medical Stocks Lagging Delcath Systems (DCTH) This Year? Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.
businesswire.com Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of…
zacks.com Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.
zacks.com 5 Stocks With Recent Price Strength Buoyed by a Strong August EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
businesswire.com Delcath Systems to Participate in Upcoming Investor Conferences QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…
zacks.com What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now? Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our…
zacks.com Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable,…
zacks.com Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our…
zacks.com Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable,…
benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $32 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $30 to $32.
seekingalpha.com Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
benzinga.com BTIG Maintains Buy on Delcath Systems, Raises Price Target to $21 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $17 to $21.
marketbeat.com Delcath Systems Q2 Earnings Call Highlights Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and…
zacks.com Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a…
benzinga.com Delcath Systems Q2 EPS $0.07 Beats $(0.09) Estimate, Sales $29.133M Beat $26.259M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.09) by 177.78 percent. This is unchanged from the same period last year.…
benzinga.com Delcath Systems Sees FY2026 Sales $104.000M-$108.000M vs $103.242M Est Delcath Systems (NASDAQ:DCTH) sees FY2026 sales of $104.000 million-$108.000 million vs $103.242 million analyst estimate.
businesswire.com Delcath Systems Reports Second Quarter 2026 Results and Business Highlights QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial…
businesswire.com Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced…- benzinga.com Delcath Systems Q1 EPS $(0.03) Beats $(0.10) Estimate, Sales $24.994M Beat $23.383M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.10) by 70 percent. This is a 200 percent decrease over earnings of $0.03…
benzinga.com Delcath Systems' CHEMOSAT M-PHP Recognized As Recommended Liver-Directed Therapy For Metastatic Uveal Melanoma In 2026 ESMO–EURACAN Guidelines Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for…- benzinga.com BTIG Maintains Buy on Delcath Systems, Lowers Price Target to $19 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the price target from $23 to $19.
- benzinga.com Delcath Systems FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
- benzinga.com Delcath Systems Q4 EPS $(0.05) Beats $(0.06) Estimate, Sales $20.728M Beat $20.326M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 19.35 percent. This is a 54.55 percent increase over losses of…
benzinga.com Delcath Systems Q4 Earnings Assessment 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $30 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $30 price target.
benzinga.com Under the Radar: 3 Microcap Growers Passing a Tough Test - benzinga.com Delcath Systems Publishes Phase 3 FOCUS Subgroup Analyses Showing Consistent Efficacy And Safety Of HEPZATO KIT In Unresectable Metastatic Uveal Melanoma In The Journal Of Cancer Research And Clinical Oncology Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
- benzinga.com Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Delcath Systems Announces $25M Buyback Plan Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of…
- benzinga.com Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
benzinga.com Stephens & Co. Maintains Overweight on Delcath Systems, Lowers Price Target to $18 Stephens & Co. analyst Sudan Loganathan maintains Delcath Systems (NASDAQ:DCTH) with a Overweight and lowers the price target from $25 to $18.- benzinga.com Delcath Systems Q3 EPS $0.02 Beats $0.01 Estimate, Sales $20.563M Miss $20.907M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 185.71 percent. This is a 66.67 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $21 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Lowers Price Target to $30 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the price target from $31 to $30.
benzinga.com Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - benzinga.com Reported Saturday, Delcath Systems Posts $20.5M Q3 Revenue, $0.8M Net Income And 87% Gross Margin; Sees 2025 Revenue Outlook Of $83M–$85M With 150% Treatment Volume Growth Forecast Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEPZATO KIT revenue of $19.2 millionCHEMOSAT revenue of $1.3 millionGross…
- benzinga.com Delcath Systems Announces The Acceptance Of An Oral Presentation On Results From The Investigator-Initiated CHOPIN Randomized Phase 2 Trial At The 2025 European Society For Medical Oncology Annual Congress Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on…
benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $31 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $29 to $31.- benzinga.com Delcath Systems Q2 EPS $0.07 Beats $0.02 Estimate, Sales $24.16M Beat $22.83M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02 by 204.35 percent. This is a 114.58 percent increase over losses of…